Investing.com - ProPhase Labs reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
ProPhase Labs announced earnings per share of $0.060 on revenue of $24.2M. Analysts polled by Investing.com anticipated EPS of $0.190 on revenue of $18.42M.
ProPhase Labs shares are down 24% from the beginning of the year, still down 22.36% from its 52 week high of $15.25 set on July 11.
ProPhase Labs shares lost 17.65% in pre-market trade following the report.
ProPhase Labs follows other major Healthcare sector earnings this month
ProPhase Labs's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar